1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin2021, 71(3):209-249.
2. Llovet JM, Montal R, Sia D, Finn RS: Molecular therapies and precision medicine for hepatocellular carcinoma. Nature reviews Clinical oncology2018, 15(10):599-616.
3. Lin DC, Mayakonda A, Dinh HQ, Huang P, Lin L, Liu X, Ding LW, Wang J, Berman BP, Song EWet al: Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. Cancer Res2017, 77(9):2255-2265.
4. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell2017, 169(7):1327-1341.e1323.
5. Dhanasekaran R: Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)-Multi-Omic and Singulomic Approaches. Seminars in liver disease2021, 41(1):9-18.
6. Qiu Z, Li H, Zhang Z, Zhu Z, He S, Wang X, Wang P, Qin J, Zhuang L, Wang Wet al: A Pharmacogenomic Landscape in Human Liver Cancers. Cancer cell2019, 36(2):179-193.e111.
7. Nam AS, Chaligne R, Landau DA: Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nature reviews Genetics2021, 22(1):3-18.
8. Chan LK, Tsui YM, Ho DW, Ng IO: Cellular heterogeneity and plasticity in liver cancer. Seminars in cancer biology2021.
9. Sonneveld S, Verhagen BMP, Tanenbaum ME: Heterogeneity in mRNA Translation. Trends in cell biology2020, 30(8):606-618.
10. Bonnal SC, López-Oreja I, Valcárcel J: Roles and mechanisms of alternative splicing in cancer - implications for care. Nature reviews Clinical oncology2020, 17(8):457-474.
11. Dvinge H, Guenthoer J, Porter PL, Bradley RK: RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing. Genome research2019, 29(10):1591-1604.
12. Zhang J, Zhang YZ, Jiang J, Duan CG: The Crosstalk Between Epigenetic Mechanisms and Alternative RNA Processing Regulation. Frontiers in genetics2020, 11:998.
13. Lópezotín C, Matrisian LM: Emerging roles of proteases in tumour suppression. 2007, 7(10):800-808.
14. Salameh MA, Radisky ES: Biochemical and structural insights into mesotrypsin: an unusual human trypsin. Int J Biochem Mol Biol2013, 4(3):129-139.
15. Rinderknecht H, Renner IG, Abramson SB, Carmack C: Mesotrypsin: a new inhibitor-resistant protease from a zymogen in human pancreatic tissue and fluid. Gastroenterology1984, 86(4):681-692.
16. Nyaruhucha CN, Kito M, Fukuoka SI: Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance. The Journal of biological chemistry1997, 272(16):10573-10578.
17. Wiegand U, Corbach S, Minn A, Kang J, Müller-Hill B: Cloning of the cDNA encoding human brain trypsinogen and characterization of its product. Gene1993, 136(1-2):167-175.
18. Tóth J, Siklódi E, Medveczky P, Gallatz K, Németh P, Szilágyi L, Gráf L, Palkovits M: Regional distribution of human trypsinogen 4 in human brain at mRNA and protein level. Neurochemical research2007, 32(9):1423-1433.
19. Cottrell GS, Amadesi S, Grady EF, Bunnett NW: Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. The Journal of biological chemistry2004, 279(14):13532-13539.
20. Nakanishi J, Yamamoto M, Koyama J, Sato J, Hibino T: Keratinocytes Synthesize Enteropeptidase and Multiple Forms of Trypsinogen during Terminal Differentiation. Journal of Investigative Dermatology2010, 130(4):944.
21. Jiang G, Cao F, Ren G, Gao D, Bhakta V, Zhang Y, Cao H, Dong Z, Zang W, Zhang Set al: PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut2010, 59(11):1535-1544.
22. Hockla A, Miller E, Salameh MA, Copland JA, Radisky DC, Radisky ES: PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Molecular cancer research : MCR2012, 10(12):1555-1566.
23. Ghilardi C, Silini A, Figini S, Anastasia A, Lupi M, Fruscio R, Giavazzi R, Bani MR: Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. Oncotarget2015, 6(29):28389-28400.
24. Ma H, Hockla A, Mehner C, Coban M, Papo N, Radisky DC, Radisky ES: PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma. Sci Rep2019, 9(1):1844.
25. Han S, Lee CW, Trevino JG, Hughes SJ, Sarosi GA, Jr.: Autocrine extra-pancreatic trypsin 3 secretion promotes cell proliferation and survival in esophageal adenocarcinoma. PloS one2013, 8(10):e76667.
26. Ma R, Ye X, Cheng H, Ma Y, Cui H, Chang X: PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer. Gynecologic oncology2015, 137(3):546-552.
27. Radisky ES: PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine. Asian journal of andrology2013, 15(4):439-440.
28. Terada T, Ohta T, Minato H, Nakanuma Y: Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Human pathology1995, 26(7):746-752.
29. Qian L, Gao X, Huang H, Lu S, Cai Y, Hua Y, Liu Y, Zhang J: PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast. Oncotarget2017, 8(13):21444-21453.
30. Schaid DJ, McDonnell SK, FitzGerald LM, DeRycke L, Fogarty Z, Giles GG, MacInnis RJ, Southey MC, Nguyen-Dumont T, Cancel-Tassin Get al: Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. European urology2021, 79(3):353-361.
31. Aboulouard S, Wisztorski M, Duhamel M, Saudemont P, Cardon T, Narducci F, Lemaire AS, Kobeissy F, Leblanc E, Fournier Iet al: In-depth proteomics analysis of sentinel lymph nodes from individuals with endometrial cancer. Cell reports Medicine2021, 2(6):100318.
32. Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT: Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis2007, 28(8):1745-1751.
33. Marsit CJ, Chinedu O, Hadi D, Kelsey KT: Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer. Molecular Carcinogenesis2010, 44(2):146-150.
34. Keishi Y, Koshi M, Hiroshi I, Masaki M, David S: A tumor-suppressive role for trypsin in human cancer progression. Cancer Research2003, 63(20):6575-6578.
35. Lin B, Zhou X, Lin S, Wang X, Zhang M, Cao B, Dong Y, Yang S, Wang JM, Guo Met al: Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma. Journal of molecular medicine (Berlin, Germany)2017, 95(11):1237-1249.
36. Marsit CJ, Karagas MR, Schned A, Kelsey KT: Carcinogen exposure and epigenetic silencing in bladder cancer. Annals of the New York Academy of Sciences2006, 1076:810-821.
37. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors Fet al: A pathology atlas of the human cancer transcriptome. Science (New York, NY)2017, 357(6352).
38. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z: GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids research2017, 45(W1):W98-w102.
39. Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, 3rd, Barretina J, Gelfand ET, Bielski CM, Li Het al: Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature2019, 569(7757):503-508.
40. Ben-David U, Siranosian B, Ha G, Tang H, Oren Y, Hinohara K, Strathdee CA, Dempster J, Lyons NJ, Burns Ret al: Genetic and transcriptional evolution alters cancer cell line drug response. Nature2018, 560(7718):325-330.
41. Deng M, Brägelmann J, Kryukov I, Saraiva-Agostinho N, Perner S: FirebrowseR: an R client to the Broad Institute's Firehose Pipeline. Database : the journal of biological databases and curation2017, 2017.
42. Guo Y, Peng Y, Gao D, Zhang M, Yang W, Linghu E, Herman JG, Fuks F, Dong G, Guo M: Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma. Clin Epigenetics2017, 9:116.
43. Lin S, Wang X, Pan Y, Tian R, Lin B, Jiang G, Chen K, He Y, Zhang L, Zhai Wet al: Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A. Clinical cancer research : an official journal of the American Association for Cancer Research2019, 25(3):1050-1062.
44. Li Y, McGrail DJ, Xu J, Mills GB, Sahni N, Yi S: Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation. Trends in biochemical sciences2018, 43(8):576-592.
45. Belluti S, Rigillo G, Imbriano C: Transcription Factors in Cancer: When Alternative Splicing Determines Opposite Cell Fates. Cells2020, 9(3).
46. Cohen I, Coban M, Shahar A, Sankaran B, Hockla A, Lacham S, Caulfield TR, Radisky ES, Papo N: Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin. The Journal of biological chemistry2019, 294(13):5105-5120.
47. Tani T, Kawashima I, Mita K, Takiguchi Y: Nucleotide sequence of the human pancreatic trypsinogen III cDNA. Nucleic acids research1990, 18(6):1631.
48. Ramesh V, Ganesan K: Integrative functional genomic analysis unveils the differing dysregulated metabolic processes across hepatocellular carcinoma stages. Gene2016, 588(1):19-29.
49. Urbanski LM, Leclair N, Anczuków O: Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley interdisciplinary reviews RNA2018, 9(4):e1476.
50. Duchmann M, Itzykson R: Clinical update on hypomethylating agents. International journal of hematology2019, 110(2):161-169.
51. Rowen L, Williams E, Glusman G, Linardopoulou E, Friedman C, Ahearn ME, Seto J, Boysen C, Qin S, Wang Ket al: Interchromosomal segmental duplications explain the unusual structure of PRSS3, the gene for an inhibitor-resistant trypsinogen. Molecular biology and evolution2005, 22(8):1712-1720.
52. Gopi LK, Kidder BL: Integrative pan cancer analysis reveals epigenomic variation in cancer type and cell specific chromatin domains. Nature communications2021, 12(1):1419.
53. Sharma A, Merritt E, Hu X, Cruz A, Jiang C, Sarkodie H, Zhou Z, Malhotra J, Riedlinger GM, De S: Non-Genetic Intra-Tumor Heterogeneity Is a Major Predictor of Phenotypic Heterogeneity and Ongoing Evolutionary Dynamics in Lung Tumors. Cell reports2019, 29(8):2164-2174.e2165.
54. Calviello L, Hirsekorn A, Ohler U: Quantification of translation uncovers the functions of the alternative transcriptome. Nature structural & molecular biology2020, 27(8):717-725.
55. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G: Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer cell2014, 26(4):577-590.
56. Demircioğlu D, Cukuroglu E, Kindermans M, Nandi T, Calabrese C, Fonseca NA, Kahles A, Lehmann KV, Stegle O, Brazma Aet al: A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters. Cell2019, 178(6):1465-1477.e1417.
57. Gomez L, Odom GJ, Young JI, Martin ER, Liu L, Chen X, Griswold AJ, Gao Z, Zhang L, Wang L: coMethDMR: accurate identification of co-methylated and differentially methylated regions in epigenome-wide association studies with continuous phenotypes. Nucleic acids research2019, 47(17):e98.
58. Schoenfelder S, Fraser P: Long-range enhancer-promoter contacts in gene expression control. Nature reviews Genetics2019, 20(8):437-455.
59. Gallego-Paez LM, Bordone MC, Leote AC, Saraiva-Agostinho N, Ascensão-Ferreira M, Barbosa-Morais NL: Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems. Human genetics2017, 136(9):1015-1042.
60. Louadi Z, Yuan K, Gress A, Tsoy O, Kalinina OV, Baumbach J, Kacprowski T, List M: DIGGER: exploring the functional role of alternative splicing in protein interactions. Nucleic acids research2021, 49(D1):D309-d318.
61. Enhancing GTEx by bridging the gaps between genotype, gene expression, and disease. Nature genetics2017, 49(12):1664-1670.